INTRODUCTION
Fibrosis (from Latin fiber = filament, thread) is defined as an excessive deposition of collagenous and noncollagenous extracellular matrix (ECM) components in organs and tissues as a consequence of proliferation and activation of fibroblasts and myofibroblasts. The latter are still not unequivocally defined by characteristic markers and can develop from both fibroblasts and nonfibroblastic cells by transdifferentiation triggered by proinflammatory and profibrotic cytokines produced by cells of the innate and adaptive immune systems.
Fibrosis is an important but surprisingly neglected worldwide health problem that is not only of medical but also of major socioeconomic relevance affecting the workforce, e.g., via postinfectious fibrotic complications, connective tissue diseases, or atherosclerosis, and it develops as a consequence of several underlying primary diseases (see Table 1 ). In fact, current health statistics indicate that nearly 45% of all natural deaths in the Western world can be attributed to chronic fibroproliferative diseases (1) . Unfortunately, basic knowledge of the molecular and cellular mechanisms that underlie the development of fibrosis has not yet translated into clinically applicable diagnostic, preventive, and therapeutic measures.
The first message of this review, based on work from many laboratories including our own, is that (a) in all forms of fibrosis, inflammatory-immunologic reactions take place in the earliest stages, promoting subse- Table 1 Major causes of fibrosis
Tissue damage
Postoperative, burns, liver cirrhosis, etc.
Infections and autoimmune diseases 3. Foreign material
Silicone implants (e.g., silicone mammary implants, gastric banding)
"Spontaneous"
Dupuytren's contracture, Peyronie's disease
Tumors
Tumor stroma, fibroma, etc.
quent profibrotic processes, and (b) elements of both the innate and adaptive immune systems are involved in this sequence of events (2) . In other words: No inflammation, no fibrosis. This concept is schematically illustrated in Figure 1 . The second message is that, despite the diverse diseases and molecular pathways that initiate the fibrotic process, the biochemical and cellular mechanisms that lead to the final outcome of fibrosis are stereotypical in all instances. These common essential pathways may be further fine-tuned by nonessential individual modulating factors such as products of arachidonic acid metabolism. These final pathways leading to excessive production of collagenous and noncollagenous ECM constituents are either effective directly in fibroblasts that preexist in situ or via so-called myofibroblasts that are formed by transdifferentiation of cells from various other origins. Thus, Dulauroy et al. (3) have shown that, after tissue damage, perivascular cells of the ADAM 12 (a disintegrin and metalloproteinase 12) lineage detach from capillaries, migrate to the interstitial space, become activated, proliferate, and transform into myofibroblasts producing ECM molecules.
BASIC MECHANISMS Innate Immunity and Fibrosis
Early during the pathogenesis of fibrosis, neutrophils (during bacterial infections), eosinophils (during parasite infections), monocytes/macrophages, mast cells, and lymphoid cells including natural killer/natural killer T (NK/NKT) cells are found in the affected areas. Thus, clearly distinguishing the relative contributions of the innate and adaptive immune systems is not possible, and interactions between these systems have not been fully elucidated. Hypotheses concerning the initial host-defense mechanisms that initiate fibrosis include infection, reactive oxygen species (ROS), nitric oxide, toxic and mechanical stress (e.g., at arterial predilection sites for atherosclerotic lesions), altered self-components, and MMP: matrix metalloproteinase reactions to noninfectious foreign material (2) . Stimulation of cellular components of the innate immune system may lead either to the release of preformed profibrotic factors or to the production and secretion of newly synthesized factors, notably profibrotic cytokines.
Thus, the granules of neutrophils, the main effectors of acute inflammation, contain numerous enzymes, many of them of direct relevance in the present context in two ways: On the one hand, enzymes such as matrix metalloproteinases (MMPs), elastase, and cathepsins are released that can specifically cleave collagenous and noncollagenous connective tissue components that are instrumental in tissue remodeling in the course of fibrosis; on the other hand, neutrophils play an indirect role by activating further cellular components of the innate immune system that promote fibrogenesis (4) . Thus, activated macrophages produce TNF-α and IL-1 that in turn activate fibroblasts and induce overproduction of ECM proteins. TNF-α-triggered signal transduction leading to the expression of fibrogenic cytokines is mainly effective via the NF-κB pathway. In contrast, antifibrotic effects are exerted by interferon (IFN)-γ produced by activated NK cells, as is detailed below.
As will become evident throughout this review, stimulation of the immune system via Toll-like receptors (TLRs) is a common proinflammatory triggering mechanism in all forms of fibrosis. Thus, in a murine model of pulmonary fibrosis, IL-1R1/TLR-MyD88 signaling is essential for the profibrotic activity of IL-1 (5) . In addition to IL-1, activation of other proinflammatory cytokines following inflammasome assembly, such as IL-18, promotes fibrosis. Also, components of the inflammasome proper, such as the adaptive protein inflammasome adaptor protein ASC, have been associated with the development of fibrosis (6, 7) .
Eosinophils, like polymorphonuclear granulocytes, also frequently participate in the early inflammatory stages of fibrosis (8) . Eosinophil granules contain and release basic proteins such as the major basic protein (MBP), lysosomal hydrolytic enzymes, and eosinophilic peroxidase. Pathogenesis of fibrosis: Tissue injuries caused by infection, foreign bodies, mechanical stress, autoimmune reactions, or neoplasia activate the immune system and repair mechanisms. Effective healing is usually characterized by a dominant Th1 response, whereas a predominant Th2 response and an increase in Th17 cells lead to chronic inflammation, which can ultimately result in fibrosis. (Abbreviation: Myo-FB, myofibroblast.)
Tissue eosinophilia is associated with various fibrotic conditions, including endomyocardial fibrosis, fibrotic changes beneath the alveolar basement membrane in patients with bronchial asthma, and toxic oil syndrome (9) . Interestingly, extracts of eosinophils stimulate fibroblast proliferation, which points to a profibrotic role of eosinophilic products. Indeed, MBP-1 has profibrotic properties (10) . Mast cells are an important constituent of chronic inflammatory infiltrates. Claman (11) was the first to point out, in 1985, that mast cells-in addition to their known role in inflammation in general-also influence the fibrotic response, and in turn, mast cell differentiation may be influenced by the surrounding connective tissue milieu. Since then, several papers have reported fibroblast chemotaxis and pro-type I collagen expression upon treatment with mast cell tryptase that can be blocked by tryptase inhibitors (12) .
TIMP: tissue inhibitor of matrix metalloproteinase
Mast cell-deficient mice are relatively resistant to bleomycin-induced lung fibrosis. In the tight-skin mouse model of fibrosis, depletion of mast cells also prevents dermal thickening. Tryptase is bound to and stabilized by heparin within mast cell granules. Dissociated from heparin and released together with histamine (facilitating cellular and humoral penetration of the infiltrated tissue), it then exerts its various effects, including stimulation of fibroblast proliferation, expression of collagen (e.g., types I and VI), and cleavage of the latent form of stromelysin (MMP-3), thus participating in the orchestration of fibrosis (13) . Fibroblast stimulation is enhanced via the synthesis of cyclooxygenase and prostaglandins.
From a quantitative viewpoint, i.e., contemplating the composition of chronic inflammatory mononuclear cell infiltrates in the early phases of fibrotic tissue formation, monocytes that later transform into sessile macrophages seem to be the major players in fibrogenesis. The exact defense mechanisms exerted by them are still not clear, however, and may depend on the initial event triggering inflammation, e.g., infection, reaction to altered self, mechanical stress, inorganic foreign material (e.g. silicone implants), or ROS. Irrespective of the underlying damaging agents, the missing link between all these processes is proposed to be the Nalp3 (cryopyrin) inflammasome (7) . Macrophages are the main producers of MMPs as well as of the counteracting tissue inhibitors of matrix metalloproteinases (TIMPs). A balance between MMPs and TIMPs is crucial for the deposition and breakdown, respectively, of the collagenous ECM proteins. MMP-13 gene expression is restricted to regions of fibrosis. Thus, MMP-13 production by liver macrophages is significantly reduced after chemically induced liver damage. An interesting model for these types of studies is the CD11b-diphtheria toxin receptor transgenic mouse in which scar-associated macrophages could be selectively depleted. CCL2, which binds to the CCR2, mediates fibrosis of kidney and liver, and CCR2 knockout mice are partly protected from inflammation-induced fibrosis (14) .
The two known macrophage subpopulations, namely inflammatory M1 and patrolling M2 macrophages, can be differentiated by surface markers and protein expression profiles, including the CCR2 and migratory responses to the chemokine ligands CCL2, CX3CL1, and CCL5. After recruitment, monocytes differentiate into classically activated proinflammatory M1 macrophages if they come into contact with macrophage-colony stimulating factor (M-CSF), bacterial lipopolysaccharide (LPS), TNF-α, or IFN-γ. They may also take the path to alternatively activated, anti-inflammatory M2 macrophages as a consequence of being stimulated with granulocyte-macrophage CSF (GM-CSF), IL-4, or IL-13 (15) . Thus, for instance, as an infection subsides, monocytes attracted to the site of inflammation become less aggressive M2 macrophages with greater capacity for the induction of other mononuclear cells to produce angiogenic and fibrogenic cytokines, notably IL-4, IL-10, IL-13, and transforming growth factor (TGF)-β1. IL-4 and IFN-γ released by lymphocytes suppress MMP biosynthesis by macrophages without affecting TIMP production.
In conclusion, different subpopulations of macrophages can either (a) mediate destruction of ECM directly or indirectly by inducing release of MMPs by stromal cells (M1) or (b) support cellular proliferation and stimulate production and stabilization of already deposited ECM components and synthesis as well as secretion of new ECM molecules (M2). Furthermore, phagocytosis of apoptotic cells by macrophages in the course of inflammation and healing brings about a change from cell-killing, matrix-degrading cells to matrixgenerating, proliferating, tissue-healing cells.
NK and NKT cells display mainly antifibrotic characteristics. Thus, SCID-Beige mice lacking T, B, and NK cells are more susceptible to chemically induced liver fibrosis than are healthy controls, even after T cell reconstitution (16) . Bleomycin-treated NKT cell-deficient mice also develop more severe lung fibrosis than do wild-type controls (17 effects, and this mechanism also seems to underlie the antifibrotic properties of NKT cells via either induction of cell cycle arrest or apoptosis of hepatic stellate cells (HSCs), depending on the induction of the STAT1 transcription factor (18) . In fact, most data on the antifibrotic effects of NK/NKT cells derive from studies on liver fibrosis. Importantly, IFN-γ also downregulates the expression of TGF-β1 (19) .
Adaptive Immunity and Fibrosis
Effector mechanisms. The presence of IL-12 at the time of T cell priming drives Th1 differentiation, and that of IL-4 drives Th2 differentiation. Th1 cells produce proinflammatory cytokines (IFN-γ and IL-2) and are responsible for phagocyte-dependent protective host responses. Th2 cells secrete anti-inflammatory cytokines (IL-4, IL-10, and IL-13), and IL-5 has been considered responsible for the phagocyte-independent protective host responses. The Th1/Th2 paradigm has been further strengthened by in vitro and in vivo data showing an antagonism between Th1 and Th2 lymphokines. IL-4 promotes Th2 development and antagonizes Th1 development, whereas IFN-γ and IL-2 promote Th1 development and antagonize Th2 development.
Th17 cells are a more recently described effector CD4 + T cell subset characterized by the production of IL-17A, IL-17F, and IL-22. It has been postulated that an imbalance between Th1/Th2/Th17 cell subsets drives inflammation in the early stages of disease (Th1 and Th17 predominant) and fibrosis in the later stages (Th2 predominant). Thus, profibrotic and proangiogenic properties are preferentially provided by fibroblasts under the influence of Th2-like cells (Figure 2) .
Th17 and other IL-17A-producing T cells, including a population of γδ T cells and NKT cells, have also been associated with the development of different fibrotic diseases. However, IL-17-producing T cells play important roles in protective immunity against some bacterial infections, mainly through the recruitment and activation of neutrophils. Thus, excessive or deficient IL-17 elaboration leads either to deficient responses or to disease.
Recent data in a mouse model of pulmonary fibrosis using Bacillus subtilis infection have demonstrated that a direct blockade of IL-22 enhances collagen deposition in the lung, whereas administration of recombinant IL-22 inhibits lung fibrosis (20) . Moreover, the presence of protective γδ T cells and IL-22 diminishes recruitment of CD4 + T cells to the lung. These data indicate the existence of a protective pathway that involves the inhibition of αβ T cells by regulatory IL-22-secreting γδ T cells. Although synergy between IL-17A and IL-22 cannot be excluded, these data support the concept that IL-17A-expressing γδ T cells promote microbial elimination, whereas the IL-22-expressing population limits lung inflammation and fibrosis. Whether IL-17A and IL-22 protect or promote lung inflammation and fibrosis in models of hypersensitive pneumonitis seems to be dependent on the inhaled antigen. Thus, repeated exposure to Saccharopolyspora rectivirgula results in inflammation and fibrosis mediated by Th17-polarized CD4 + T cells, whereas after exposure to B. subtilis, IL-17-producing γδ T cells-which play critical roles in bacterial clearance and resolution of inflammation-are expanded (21) . Concurrently, IL-17A-producing γδ T cells and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis (22 (29) . These contradictory findings of Treg involvement in fibrosis may be explained by the (im)balance between the degree of inflammatory response suppression and TGF-β1 production. In most instances, only Tregs harvested from peripheral blood (rather than the fibrotic tissue itself ) were studied. We return to this important issue below in the subsection entitled Foreign Body-Induced Fibrosis.
A recent highly promising field of research concerns the dependence of Treg development, maturation, and differentiation on components of the micromilieu where these processes take place. In addition to the effect of tolerogenic cytokines, such as IL-10 and TGF-β1, certain ECM components are crucial to the induction and preservation of immunological tolerance. Thus, hyaluronan, an important noncollagenous constituent of the pericellular glycocalyx, affects the survival of Tregs (30) . Together with other mechanisms, high-molecular-weight hyaluronan seems to be jointly responsible for the maintenance of immunological homeostasis in intact, uninjured tissue by providing a signal that "everything is within normal range," so that adaptive immune reactions are downregulated by Tregs after the integrity of the lesioned tissue has been reconstituted.
FIBROTIC DISEASES

Repair of Tissue Damage
Wound healing and scar formation. Wound healing is one of the most complex biological processes that occur during human life and leads either to restituto ad integrum or to a nonfunctioning mass of fibrotic tissue known as a scar. In all organ systems, the wound repair process occurs in three overlapping but distinct phases: initial inflammation followed by proliferation and remodeling.
Early after a skin wound, there is an influx of neutrophils, monocytes, and mast cells to the site of injury. As cells are damaged or killed in the wounding process, they release uric acid crystals as well as other endogenous danger signals that activate inflammasomes, such as Nalp3 (2, 7). The release of platelet degranulation products, such as platelet-derived growth factor (PDGF) and TGF-β1, as well as the upregulation of diverse other cytokines and chemokines (e.g., IL-1, CXCL8, and CXCL1) regulate this initial innate immune response. Neutrophils remove infectious and noninfectious foreign material and damaged matrix components by phagocytosis. Macrophages release multiple cytokines [IL-1, IL-6, TNF-α, TGF-β1, and insulin-like growth factor-1 (IGF-1)] that regulate endothelial cell proliferation, angiogenesis, fibroblast proliferation, and ECM synthesis, which finally form the scar tissue (31) . Macrophages can also express inducible nitric oxide synthase (iNOS) in the early phase of wound healing. In murine models, inhibition of iNOS significantly impairs reepithelialization and decreases collagen deposition. Mast cells also play a role in wound healing by their secretion of tryptase, which contributes to connective tissue breakdown, which in turn leads to a more penetrable milieu for infiltrating leukocytes during inflammation. As mentioned above, mast cell tryptase indirectly induces fibroblast proliferation (32, 33) .
Moreover, the role of T cells, in particular that of dendritic epidermal T cells (γδDETC, γδ T cells), in epidermal wound repair has been discussed. These T cells recognize antigensso far unidentified-expressed by damaged cells and produce fibroblast growth factors (FGF-7 and -10) as well as IGF-1, thereby regulating keratinocyte proliferation and differentiation (34) . trauma, inflammation, surgery, or burns (35, 36) . Clinically, a keloid behaves like a benign tumor as it infiltrates adjacent healthy tissue but does not metastasize and rarely regresses over time. The excessive scarring in keloids is caused by increased proliferation and an excessive deposition of collagen by fibroblasts. Keloid formation is always associated with an abnormal fibroblast response to inflammation. Significant mast cell numbers and abnormal clustering of these cells at the margin of keloids have been described (37) .
IL-6 plays an important role in fibroproliferative diseases in general and keloids in particular. IL-6 reportedly increases MMP-1 and TIMP-1 expression as well as collagen synthesis, whereas IL-6-deficient mice exhibit impairment in skin wound healing, with higher numbers of macrophages and lymphocytes (38) . Although the initial high CD4:CD8 T cell ratio decreases as the normal wound heals, this ratio remains high in keloids, and CD4 + T cells display an activated phenotype (Figure 3a ). Blood mononuclear cells from patients with keloids display an upregulation of TNF-α, IL-6, and IFN-β and a downregulation of IFN-α, IFN-γ, and TNF-β (39).
Burns. Thermal injury remains a significant health problem, with approximately 50,000 people in the United States each year sustaining burns requiring hospitalization (40) . In a mouse burn model, a significant increase in tissue levels of IL-17 and IL-22 at 3 h after major burn at the site of injury was shown as compared to sham (shaved but nonburned) skin. The early IL-17 elevation in burned skin is consistent with previous findings showing elevated levels in lung injury models 4 h after injury and in sepsis models. Although the precise role of IL-17 in the early postburn phase needs to be further elucidated, previous studies in other experimental animal models have suggested a role for IL-17 in the recruitment of neutrophils and monocytes and in combating infection (41) . In this context, γδ T cells are an important source of IL-17 (42) . A γδ T cell-deficient mouse burn injury model displayed markedly less inflammation, edema, and immune cell infiltration than burn wounds from wild-type mice, resulting in delayed wound healing. Moreover, burn injuries are also associated with a higher incidence of hypertrophic scarring.
Acute respiratory distress syndrome (ARDS), a severe complication after major thermal injury, develops because of an overwhelming inflammatory response that involves activation of various inflammatory cells and excessive cytokine release. ARDS is described as a stereotyped response to injury with transition from alveolar capillary damage to a fibroproliferative phase. TLRs are highly expressed in lung tissue and can be activated by either microbial or endogenously derived ligands [heat shock proteins (HSPs), necrotic cells, hyaluronic acid] (43, 44) . Significantly increased TLR2-and TLR4-mediated inflammation triggered by various ligands has been found in bronchoalveolar lavage cells (IL-6, IL-17, CCL2, CCL4, TNF-α, and CCL5) of a mouse burn model seven days after injury (45) . Besides secreting numerous proinflammatory cytokines (IL-1β, IL-4, and IL-13), alveolar macrophages also secrete growth factors (TGF-α, TGF-β1, PDGF, FGF, and IGF-1), which influence mesenchymal cell migration, proliferation, and ECM deposition, thus engaging them in the progression of fibroproliferative lung disorders (46) . Concerning the activation of the humoral immune system, various autoantibodies have been detected in the sera of patients with thermal burns (47) (48) (49) . Major thermal injury decreases the Th1 response and enhances the Th2 response, leading to immune paralysis and increased susceptibility to sepsis.
Alcoholic liver cirrhosis. Alcoholic liver cirrhosis, in contrast to autoimmune hepatitis, for instance, is a paradigmatic example of a fibrotic disease developing after toxic damage to a parenchymatous organ. The first, still reversible, stage is alcoholic hepatitis, mediated by both innate and adaptive immunity (50, 51) . Already at this stage, circulating autoantibodies against acetaldehyde adducts and lipid peroxidation-derived antigens (52, 53) (57) . In summary, alcohol first leads to a breakdown of the intestinal-blood barrier, resulting in chronic endotoxemia. LPS causes activation of monocytes/macrophages in general and hepatic Kupffer cells in particular, mainly via the CD14/TLR4 pathway manifested by oxidant (ROS) and cytokine (TNF-α, CXCL8) production. Neutrophils are then recruited to the liver and-together with the activated Kupffer cells-phagocytose bacterial antigens and release proteolytic enzymes as well as additional oxidants and chemoattractants. NK and NKT cells are activated by TNF-α and IFN-γ available within the inflammatory foci in the liver. Biochemically (e.g., oxidized, acetaldehyde-modified) altered liver cell antigens are finally recognized by T cells (with a preponderance of CD8 + but also important fractions of Th1/Th17 cells), resulting in the development of an alcohol-induced autoimmune liver disease. Necrotic and apoptotic liver cells are continuously replaced by fibrotic scar tissue produced by fibroblasts, myofibroblasts, and HSCs.
Among the many cells of the innate immune system that are affected by alcohol, the most important within the liver itself are specialized intrasinusoidal macrophages, the Kupffer cells. They are activated by LPS derived from alcohol-driven leakiness of the gut (58) . Neutrophils are attracted to the intoxicated liver, especially by the chemoattractant CXCL8 released by Kupffer cells (57) . The initial activation of innate immune mechanisms that is reflected, for instance, by TNF-α and IL-6 production provides the link to adaptive intrahepatic immune processes. T cells infiltrating the liver release more TNF-α as well as IFN-γ, and in experimental animals liver damage can be induced in recipients of acetaldehyde-modified liver proteins. Continuous alcohol consumption will lead to chronic hepatitis with increased production of profibrotic cytokines, especially TGF-β1, by Kupffer cells and activated T cells that in turn promote fibrogenesis via activation of HSCs (59) . HSCs, formerly called Ito cells or lipid-storing cells, are pericytes located in the perisinusoidal space, i.e., the area between sinusoids and liver cells, the so-called space of Dissé (Figure 4) . In normal liver, HSCs are quiescent and represent about 5-8% of all cells. Morphologically, the glycoprotein reelin can be used as a marker to distinguish HSCs from other myofibroblasts (60) . More recently, Th17 lymphocytes have been demonstrated within intrahepatic inflammatory lesions in alcoholic liver disease, and in parallel, increased Th17 levels were measured in the serum (61) . Similar to the end-stage of fibrosis that takes place in other inflammatory (e.g., autoimmune) conditions discussed below, the interaction between myofibroblast-like HSCs, Kupffer cells, and Th1/Th17 lymphoid cells is crucial for the final outcome of the fibrotic process. It remains to be clarified whether T cell stimulation by biochemically modified (e.g., oxidized) antigens also promotes Th2 lymphocyte recruitment and M2 macrophage polarization that might contribute to fibrogenesis.
Infection and Fibrosis
Infections are probably the most frequent causes of fibrosis, but expanding on this issue would take us too far afield from the conceptual framework of this review. Therefore, bacterial and viral infections are discussed in the context of intestinal and liver fibrosis, respectively.
In addition, fibrosis often develops as a consequence of parasitic infections. Schistosomiasis caused by Schistosoma mansoni, a paradigmatic parasitic infectious agent, exerts its important effects on morbidity and mortality mainly via its inflammatory and profibrotic role in the liver, where chronic inflammation and scar tissue develop around trapped parasite eggs (62) (63) . Degranulation of mast cells and eosinophils is a major event in this process that is based on an imbalance between fibrogenic TGF-β1 and the collagen-cleaving enzyme MMP-2 (64, 65) . Fibrotic granuloma formation in the course of parasitic infections in general and schistosomiasis in particular is a process that is tightly controlled by the host's immune system. In the acute phase, the Th1 response prevails, characterized by the production of IFN-γ and TNF-α. The deposition of eggs then leads to the transition to a Th2 response with its characteristic cytokine profile consisting of IL-4, IL-13, and IL-10. The parasitic eggs produce an IL-4-inducing factor (IL-4-inducing principle from schistosome eggs, or IPSE) that stimulates the expression of IL-4 and IL-13 by basophils (62) . In chronic schistosomiasis, a downregulation of the immune reaction can be observed (66) . B cells (67) and a pathway dependent on the stimulation of the IL-13 receptor α2 (68) as well as activated IFN-γ-producing NK cells (69) have been suggested as being responsible for this downregulation. Finally, HSCs stimulated by cytokines, including TGF-β1 produced by Th2 cells responding to schistosome antigens, transdifferentiate into myofibroblasts, producing excessive amounts of type III, VI, and I collagen (63, 70) . As detailed below, a similar final course of fibrogenic events can be demonstrated in liver fibrosis, which develops as a consequence of other, nonparasitic infectious diseases as well as of autoimmune diseases.
Autoimmune Diseases
Systemic sclerosis. SSc (or scleroderma) is an inflammatory-fibrotic autoimmune disease affecting the skin and multiple internal organs. Microvascular lesions, perivascular mononuclear cell infiltration, and increased
EndoMT:
endothelial-tomesenchymal transition deposition of collagen and other ECM proteins are the morphological hallmarks of SSc (Figure 3b) . Alterations of T cell subsets, B cell activation, and autoantibodies directed against endothelial cell antigens (anti-endothelial cell antibodies, or AECA) and various antinuclear autoantibodies (ANA) support the notion that dysfunction of the immune system drives the pathogenesis. Although the ultimate etiology is still elusive, apoptosis of microvascular endothelial cells caused by AECA-dependent cell-mediated cytotoxicity has been identified as a primary pathogenic event in SSc (71, 72) . This is followed first by a perivasculary inflammatory stage and, subsequently, by a chronic fibrotic stage, the latter finally leading to death by fibrosis of internal organs. Both the innate and adaptive immune systems play a role in the pathogenesis of SSc (73) . An aberrant TLR response by dendritic cells (DCs) showing markedly increased secretion of IL-6, TNF-α, and IL-10, especially in the early phase of disease, and decreased IL-12 might underlie the Th2 predominance and subsequent production of profibrotic cytokines. TLR4 is involved in activation of fibroblasts by antifibroblast antibodies, which induce CCL2 and CXCL8 synthesis (74) . TLR4 can also be activated by damage-associated membrane proteins (DAMPs) resulting from cell damage, oxidative stress, and ECM remodeling. Among the ECM molecules, fibronectin extra domain A (Fn EDA ) seems to be of special relevance as it is necessary for myofibroblast differentiation, and Fn EDA -null mice do not develop fibrosis after bleomycin administration (75) . Injury-induced myofibroblast differentiation might link microvascular injury to fibrosis. Thus, endothelial cells undergoing apoptosis release a C-terminal fragment of perlecan, which activates phosphoinositide 3-kinase (PI3K) in fibroblasts, leading to apoptosis resistance and myofibroblast differentiation (76) . Pericytes, i.e., mural cells of capillaries and venules, which express α-smooth muscle actin and are able to produce ECM proteins and fibroblast-activating cytokines, have also been suggested as precursor cells for myofibroblasts in SSc (77) . Another source of myofibroblasts may be endothelial cells themselves that can transdifferentiate to myofibroblasts in a process called endothelial-to-mesenchymal transition (EndoMT). Pulmonary endothelial cells stimulated by TGF-β1 differentiate into myofibroblasts, a process mediated by the tyrosine kinase c-Abl and protein kinase Cδ (PKCδ) (78) .
Fibrosis caused by excessive ECM deposition in skin and visceral organs is the most striking feature of SSc. The major component of ECM is type I collagen, which is elevated in SSc skin and the expression of which is regulated by various cytokines and growth factors at the transcriptional level. TGF-β1 is thought to be the main driver of fibrosis, and many studies have focused on its role in the pathogenesis of SSc, on its receptors, and on its downstream signaling molecules (79) . However, studies on the other TGF-β isoforms are rare, and the data arising from these investigations are contradictory. Studies in University of California at Davis line 200 (UCD-200) chickens, the only spontaneous animal model showing all hallmarks of SSc (namely, vascular alterations, inflammation, autoimmunity, and fibrosis of skin and internal organs), revealed a diminished TGF-β2 synthesis by embryonic fibroblasts and constitutive overexpression of a profibrotic procollagen α2 type I mRNA variant, suggesting that TGF-β2 is a critical antifibrotic factor early in fibrogenesis (80) . This hypothesis is supported by a microarray study on gene expression patterns in SSc skin that showed reduced TGF-β2 expression in diseased skin biopsies compared to healthy controls (81).
Atherosclerosis. Atherosclerosis, the principal cause of heart attacks, stroke, and gangrene of the extremities, is characterized by hardening (sclerosis) of the arterial wall due to pathologic fibrotic changes. This disease is responsible for more than 40% of all deaths in the Western world, with increasing numbers in developing countries. In the early 1990s, it was rediscovered that atherosclerosis begins as a chronic inflammatory-immunologic disorder of the arterial wall (82) resulting in a complex SMC: smooth muscle cell interplay between modified lipids, different cells of the immune system, endothelial cells, smooth muscle cells (SMCs), and ECM (Figure 3c) . We have shown that the very first, clinically still inapparent stage of atherosclerosis is due to an infiltration of the arterial intima by HSP60-reactive T cells at the notorious predilection sites of atherosclerotic lesions. Atherosclerosis can therefore be classified as an autoimmune disease (83, 84) with severe fibrotic alterations-so-called atherosclerotic plaques-as an end-stage leading to fatal consequences, i.e., stroke, myocardial infarction, and peripheral vascular occlusion. As in other fibrotic disorders, an imbalance between profibrotic and antifibrotic cytokines induces fibroblast proliferation and hyperproduction of ECM (85) . Furthermore, a distribution pattern of various ECM proteins exists within the atherosclerotic arteries, which leads to dramatic changes in function of the vascular SMC (86). As mentioned above, TGF-β1 is considered the most important ECM regulator. Atherosclerotic plaques are covered by a fibrous cap, and the rupture of so-called unstable plaques has deleterious effects. Thus, inhibition of TGF-β1 signaling in animal models leads to acceleration of atherosclerosis and induces an unstable plaque phenotype (87) . Moreover, specific inhibition of TGF-β1 signaling in T cells accelerates atherosclerosis and dramatically alters atherosclerotic lesion size and composition (88, 89) . In contrast to such a protective role, upregulation of TGF-β1 expression is also mainly responsible for the excessive intimal fibrocellular proliferation and inward remodeling (90) .
In addition, the inhibition of TGF-β1 can prevent constrictive remodeling, another critical component of restenosis. The inhibition of TGF-β1 decreases MMP expression, thereby reducing collagen degradation and subsequently creating an adventitial collagen scaffold to maintain the vessel circumference. An enhanced regional expression of vascular MMPs is believed to contribute to vascular SMC migration and proliferation into the intima and a weakening of the ECM that favors plaque rupture (91) . Furthermore, MMPs also promote plaque instability by inducing vascular SMC apoptosis in the fibrous cap of the plaque and thereby weakening the fibrous cap. The dysregulation between the production and enzymatic cleavage of collagenous ECM components by MMPs as well as the increased production of TIMPs (e.g., TIMP-1) can further contribute to arterial thickening and hardening (92, 93) . The main constituent of the plaque fibrotic tissue is the SMC, which contributes to most ECM components, e.g., type I and type III collagen. Several cell types contribute to the remodeling of injured arteries and to plaque formation, including local sources such as SMCs from the media and adventitial fibroblasts as well as circulating bone marrow-derived cells (94, 95) .
Fibrotic Diseases of the Intestine
As detailed in the introduction to this article, the general profibrotic mechanisms in various organs and organ systems follow a stereotypical chronological pattern. First, inflammatory processes develop that in most instances are triggered by infectious agents or autoimmunity. Thus, in fibrosis of the gastrointestinal tract, hallmarks of inflammation can first be demonstrated simultaneously with tissue damage, remodeling, and regeneration. Again, fibroblasts together with vascular pericytes and SMC can transdifferentiate into myofibroblasts. In fact, myofibroblasts can also develop from endothelial and epithelial cells. Importantly, fibroblastlike cells originating from bone marrow stem cells can be found in the circulation, provisionally termed fibrocytes, and may act as seed cells for fibrosis at any site of chronic inflammation that involves both innate and adaptive immunity. In addition to producing collagenous and noncollagenous ECM molecules, myofibroblasts are also engaged in local angiogenesis, i.e., the vascularization of scar tissue (96) . The identities of intestinal subepithelial vimentin and of α-smooth muscle actin-positive myofibroblasts that seem to be instrumental in the development of fibrosis are still matters of controversy. However, it is now clear that other
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α-smooth muscle actin-positive mesenchymal cells located in the intestinal lamina propria are also fibrogenic. These include vascular pericytes, bone marrow-derived mesenchymal and hematopoietic stem cells, mucosal SMCs, and lymphatic SMCs (97) .
In the course of damage to the intestinal tract by various types of injury, regeneration and inflammation take place, leading either to complete restitution, to muscular hypertrophy, to recurrent diverticulitis, or to inflammatory bowel disease such as Crohn's disease or ulcerative colitis.
Activation of components of the innate and adaptive immune systems within the gutassociated lymphoid tissue leads to the production of proinflammatory cytokines that not only aggravate and perpetuate the local inflammatory process but also cause proliferation of fibroblasts, transdifferentiation of various other cell types into myofibroblasts, and enhanced ECM production. Besides TGF-β1 as the most important profibrotic cytokine, IGF-1, IL-1, IL-4, IL-6, IL-13, IL-21, and CTGF also contribute to fibrosis, whereas IFN-γ, IL-10, and IL-12 have antifibrotic effects (98) . Compared to other organ systems that may be affected by fibrosis, the gastrointestinal tract of course holds a special position because it harbors the bulk of the body's microbiome. Indeed, these microbiota constitute a driving force for gastrointestinal fibrosis after breakdown of the gut-blood barrier. This occurs predominantly by stimulation of innate immunity via TLR and NOD-like receptors, which entails the development of fibrosis by the same mechanisms described above for alcoholic liver cirrhosis. Interestingly, certain variants of the Crohn's disease susceptibility gene NOD2/CARD15 (a gene that also plays a role in other diseases) seem to protect these patients from severe fibrosis that under conventional conditions leads to stricturing disease (99) . In addition to these microbial inducers of fibrosis, there is also a reaction to components of autologous damaged cells that act as DAMPs. These products include DNA, RNA, ATP, high mobility group box 1 protein (HMGB1), uric acid, ECM fragments, and various cytokines (100). Modulation of fibrogenic processes can be achieved by microRNAs (miRNA) repressing the expression of specific target genes at the posttranscriptional level (101) .
Finally, epigenetic modifications may play an important role in intestinal fibrosis because they may become fixed in affected fibroblast subpopulations, promoting and perpetuating the disease. Thus, investigators have demonstrated the presence of high levels of histone H4-lysine acetylation on the type I collagen gene promoter in human intestinal fibroblasts from patients with Crohn's disease (100). The end-stage of gastrointestinal fibrosis is a lifethreatening stricture.
Nonalcoholic Liver Fibrosis
In addition to alcoholic liver cirrhosis, liver fibrosis also develops in nonalcoholic steatohepatitis, cholestatic liver disease, and postinfectious hepatitis and is also manifested as the end-stage of an autoimmune liver disease. In virus-induced hepatitis B or C, specific cytotoxic T cells attack infected hepatocytes, resulting in massive lymphoid infiltration. In contrast, hepatitis A virus is a cytotoxic RNA virus that causes acute inflammation and liver cell death. In autoimmune hepatitis or primary biliary cirrhosis, T cells recognize specific autoantigens. In autoimmune hepatitis, these are α-smooth muscle actin, liver kidney microsomal antigens, and soluble liver/liver pancreas-or liver-cytosol-specific antigens (102) . In primary biliary cirrhosis, the multienzyme 2-Oxo-acid dehydrogenase complex contains the culprit autoantigens (103) .
In post-allotransplant liver fibrosis, recipient T cells react against donor MHC molecules. Thus, the intrahepatic inflammatory process gives rise to different pathways of lymphoid recruitment and migration, again as a sequela of primary tissue damage, in this case by antivirus, autoimmune, or alloimmune reactions.
HSCs, fibroblasts, and myofibroblasts are activated, proliferate, and produce large amounts of ECM components ( Figure 5 ). This LSEC: liver sinusoidal endothelial cell process starts in the periportal fields and from there extends into the liver cell lobuli between the hepatic trabeculae.
HSCs switch their resting type collagen production profile from type IV > III > I collagen to the still reversible III > IV > I collagen, to a final I > III > IV collagen, i.e., type I collagen-dominated irreversible stage (104) . HSCs are located in the space of Dissé and store vitamin A in lipid droplets. When stimulated with profibrotic cytokines, such as TGF-β1 and PDGF produced by Kupffer cells, quiescent HSCs transdifferentiate into activated HSCs, lose vitamin A, and upregulate the expression of α-smooth muscle actin. Vitamin A is essential for the development and functional maintenance of Tregs, but to our knowledge this fact has not yet been explicitly studied in situ in the context of liver fibrosis. The activated HSCs then produce abundant quantities of ECM, resulting in liver fibrosis, as mentioned above. Via TLR activation, HSCs can produce proinflammatory cytokines and chemokines (i.e., TNF-α, CXCL1, CCL4, CCL3, CCL2), keeping the inflammation and thus the profibrotic process going (105) . CXCL10 has also emerged as a potent profibrotic factor participating in the cross talk between hepatocytes, HSCs, and cells of the immune system (106). CXCL10-deficient mice have fewer B cells, T cells, and DCs in liver cell infiltrates after CCl 4 -intoxication. In parallel, the number and activity of HSCs are also reduced in these mice.
Under normal conditions, HSCs are important for the regulation of sinusoidal blood flow and tone. In an activated state, HSCs alter the sinusoidal structure by capillarization and impairment of blood flow, causing portal hypertension (107) . Concomitantly, both MMPs and TIMPs are upregulated. Specifically, activated HSCs induce the upregulation of MMP-2 that causes degradation of local basement membranes, followed by replacement of destroyed liver cells by interstitial scar tissue first deposited in the subendothelial space of Dissé. HSCs can also act as antigen-presenting cells.
The end-stage of fibrogenesis in this group of hepatopathologies is again identical with that described above for alcoholic liver cirrhosis, i.e., an abundance of proinflammatory and profibrotic cytokines produced by cells within hepatic mononuclear infiltrates (T cells, macrophages, HSCs, DCs), notably TGF-β1 acting via the Smad signal transduction pathway (108, 109) . The breakdown of immune tolerance in the liver may also occur because the liver sinusoidal endothelial cells (LSECs) acquire enhanced immunogenicity during hepatic fibrogenesis, thus reversing the characteristics of LSECs from a tolerogenic to an immunogenic type. Thus, unlike LSECs in the normal liver, LSECs in fibrotic livers do not veto DC priming of T cells. This may also be one of the reasons for capillarization of sinusoids in liver fibrosis.
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Kidney Fibrosis
As in any other parenchymal organ, damage to kidney-functional epithelial cells entails inflammation that, if not stopped, leads to interstitial fibrosis similar to, e.g., liver fibrosis. Leemans et al. (110) demonstrated that TLR2 activation can initiate renal inflammation during progressive kidney injury, but the absence of TLR2 does not affect the development of renal interstitial fibrosis. This is in line with the observation that TLR2 expression is upregulated in tubulointerstitial cells (myofibroblasts and macrophages) of patients with IgA nephropathy. Other authors also challenge the primary role of TLRs (TLR2 and TLR4) and the MyD88-IRAK signal transduction pathway in the development of interstitial renal fibrosis (111) . In the kidney interstitium, TGF-β1 exerts its biological profibrotic effects mainly through its downstream signaling molecules Smad2 and Smad3, whereas induction of Smad7 inhibits inflammation and fibrosis by blocking Smad2/3 and NF-κB activation (112) . Perhaps the upregulation of Smad7 expression in glomerular podocytes in the course of various renal diseases is an attempt, often unsuccessful, of the organism to prevent fibrosis and thus loss of function. Overexpression of Smad7 in mice blocks renal fibrosis and inflammatory pathways in terms of Smad2/3 and NF-κB activation, thus downregulating the expression of collagen (types I, III, IV), proinflammatory cytokines (IL-1β, IL-6), adhesion molecules/chemokines (ICAM-1, CCL2), and iNOS (113) . As a consequence, infiltration by CD4 + T cells and macrophages is suppressed. The role of tubular epithelial cells in the progression of fibrosis has long been a matter of debate. Recently, Yang and coworkers (114) showed in various animal models of renal fibrosis that cell cycle arrest of tubular epithelial cells in the G2/M phase switches normal kidney injury repair to pathologic fibrosis. Arrested tubular epithelial cells produce high amounts of TGF-β1 and CTGF, which stimulate fibroblast proliferation and collagen synthesis (114) . The molecular basis for the perpetuated activation of fibroblasts might be epigenetic modification. Induced by TGF-β1, methyltransferase Dnmt1 hypermethylates RASAL1, encoding a suppressor of the Ras proto-oncogene. This reduces RASAL1 expression and leads to persistent Ras activation, which promotes fibroblast proliferation and renal fibrosis. Epigenetic modifications can be inherited through multiple cell divisions, which might explain why activated fibroblasts fail to return to their resting state (115) .
Fibrotic changes of renal filtration apparatus (glomerulosclerosis) can be the consequence of various underlying diseases, such as diabetes, hypertension, lupus erythematosus, or urethral obstruction, or of intoxication by environmental agents or drugs. During the development of glomerulosclerosis, irrespective of the primary causes, infiltrating inflammatory cells play a major role via the induction and production of TGF-β1. In the sequence of events, stress exerted on podocytes seems to be a crucial factor. Podocytes exposed to various stressors, such as oxidative, mechanical (blood pressure) stress or stress by complement-binding autoantibodies to glomerular basement membrane antigens (Goodpasture syndrome), express angiotensin II and TGF-β1. This also explains why inhibition of angiotensin-converting enzyme has a beneficial effect on the progression of chronic kidney disease (116) .
In glomerulosclerosis, neutrophils are the first cells recruited to glomerula. Activated neutrophils degranulate, release inflammatory and profibrotic cytokines, and finally undergo apoptosis. Macrophages are the next major source of TGF-β1; then finally T cells and, less abundantly, B cells are recruited to the site of inflammation (117) . Neutrophils are prominently represented in acute poststreptococcal glomerulonephritis, IgA nephropathy (primarily affecting the glomerular mesangium), lupus nephritis, and vasculitis-associated glomerulonephritis. They are attracted by C5a and CXCL8, which are attached to endothelial cells via heparin sulfate proteoglycan. The neutrophil-derived enzymes lead to degradation of both collagenous (type IV collagen) IPF: idiopathic pulmonary fibrosis and noncollagenous (mainly laminin and nidogen) glomerular basement membrane components. Macrophages-both those arriving from outside and those present within the mesangium-then take up the remaining cellular and glomerular basement membrane debris and secrete profibrotic cytokines, notably TGF-β1. In a third wave, T cells, B cells, and mast cells participate in the chronic inflammatory process that finally leads to fusion of the inner and outer sheaths of the Bowman's capsule, resulting in the feared end-stage of glomerular fibrosis, the so-called crescent formation, which leads to the loss of renal function.
Pulmonary Fibrosis
Pulmonary fibrosis is a serious health problem that takes a significant worldwide death toll. Many of the underlying primary diseases that lead to lung fibrosis are known, the most important being chronic infections, smoking, organic and nonorganic environmental pollutants, increased pulmonary blood pressure, allergies, and autoimmune diseases. In all these instances, the molecular pathways and cellular events that lead to the final fibrotic outcome are identical to those described elsewhere in this review. In contrast to other organs, the lung is a paradigmatic organ with an enormous exposed surface where the development of fibrosis can be directly monitored by analysis of bronchoalveolar lavage fluid. Loss of alveolar type I epithelial cells (lining >95% of the alveolar surface) and endothelial cells is the consequence of initial and persistent inflammation, respectively. As a next step, proliferation of type II alveolar epithelial cells (normally lining ≤5% of the alveolar surface), i.e., cells responsible for lung surfactant production, is observed, followed by proliferation of endothelial cells and fibroblasts with transformation into myofibroblasts and finally abundant ECM production and intestinal fibrosis (118) .
Apart from these examples of lung fibrosis with known primary causes, a large fraction of patients are classified as suffering from idiopathic pulmonary fibrosis (IPF), i.e., a disease of still unknown etiology (119) characterized by an accumulation of neutrophils and mononuclear cells, followed by progressive deposition of ECM molecules in the interstitium, and finally death due to loss of lung function. The cellular injury and the subsequent early inflammatory events, possibly including a specific reaction of the adaptive immune system, in IPF are still enigmatic. However, activated macrophages certainly play a major pathogenic role. An important hallmark of IPF is massive neovascularization that leads to fusions between the systemic and the pulmonary microvasculature (120) . This is due to an imbalance between promoters (CXCL8) and inhibitors (CXCL10) of angiogenesis (121) . A preponderance of CXCL8 is also present in supernatants of IPF-derived fibroblasts cultured in vitro, whereas production of CXCL10 predominates in normal pulmonary fibroblasts. In mice, IL-12 can attenuate bleomycin-induced lung fibrosis via induction of IFN-γ (122) . Other chemokines that play important roles in the pathogenesis of IPF include CCL2 and CCL3, which exert profibrotic effects via the expression of TGF-β1 (123) . This effect by these latter cytokines can be neutralized by specific antibodies. An important profibrotic role has also been assigned to the Th2 cytokine IL-13, a potent inducer of CCL6 (124) .
These data support the importance of chemokine networks in Th2 polarization in the course of the pathogenesis of IPF. Furthermore, IL-13 seems critically important in fibrosis development in that it activates fibroblasts and myofibroblasts. One prominent downstream mediator of IL-13 is TGF-β1, which promotes an apoptosis-resistant phenotype in fibroblasts and myofibroblasts via two pathways: the focal adhesion kinase pathway and the PI3K-AKT pathway (125) . In contrast, TGF-β1 enhances apoptosis in lung epithelial cells (126) . Increased apoptosis of alveolar epithelial cells and prolonged survival of myofibroblasts are both key features of pulmonary fibrosis. A very recent study has highlighted the importance of focal adhesion kinase as a central mediator of fibrogenesis. Increased expression and activity of focal adhesion kinase was shown in fibroblast foci and remodeled vessels from patients with IPF or connective tissue diseaserelated pulmonary fibrosis, and focal adhesion kinase inhibition prevented bleomycin-induced fibrosis in mice. Furthermore, myofibroblast differentiation in response to endothelin-1 was impaired in focal adhesion kinase-deficient murine lung fibroblasts (127) . Another factor that might promote myofibroblast differentiation and survival is the microRNA miR-21. miR-21 is primarily expressed in myofibroblasts under the tight control of TGF-β1. It is upregulated in lungs of IPF patients as well as in bleomycin-induced pulmonary fibrosis, and administration of antisense probes reduces the severity of experimental fibrosis in mice (128) .
Normal human lung fibroblasts carry the Thy-1 marker (a glycophosphatidylinositollinked glycoprotein) that is absent from IPF fibroblasts. After stimulation with TGF-β1, the latter express MMP-9 that is not produced by normal Thy-1 + lung fibroblasts, dependent on the ERK1/2 signaling pathway. Thus, the loss of Thy-1 in human lung fibroblasts seems to induce a fibrogenic phenotype (129, 130) . Interestingly, similar to our own work in the UCD-200 avian scleroderma model, TGF-β2 has been shown to exert antifibrotic effects in a murine pulmonary fibrosis model, albeit via generation of tolerogenic bone marrowderived antigen-presenting cells (131) . These and other findings again support the concept that in IPF the end-stage is rather stereotypical and caused by the same profibrotic mediators, notably-but not only-TGF-β1, as in other fibrotic conditions.
Foreign Body-Induced Fibrosis
Silicone is the most common medically applied foreign material and is thus a useful example of fibrotic reactions to foreign body implants. Breast augmentation with silicone mammary implants is one of the most frequent procedures performed in aesthetic surgery. Although systemic side effects of silicone mammary implants are controversial, peri-implant fibrosis is undisputed and is the most common local side effect of these devices, with a reported incidence from 0.5% to 50% (29, 132) . Various serum proteins have been found to adhere to silicone surfaces and mediate adhesion of fibroblasts, macrophages, and ECM proteins (Figure 3d) , and this observation also forms the basis for the development of a diagnostic test to estimate the risk of fibrotic complications in breast implant carriers (133) . However, the initial events in the activation of the innate immune system are still largely unknown. Hypotheses proposed include activation of macrophages by cryptic or altered protein domains exposed on silicone surfaces or activators by silicone degradation products that are ingested by antigen-presenting cells (134, 135) . A probable candidate antigen for T cell activation in breast implant carriers is HSP60 (Figure 3e) . Activated intracapsular T cells stimulate transdifferentiation of fibroblasts to myofibroblasts via CTGF, IL-1, and TNF-α production. We have recently shown that the number of Tregs correlates inversely with the severity of capsular fibrosis (29) . Our data suggest that at an early stage of capsular fibrosis, Tregs might still delay the development of fibrosis. Several groups have reported an inverse developmental relationship between Tregs and Th17 cells. Thus, Korn et al. (136) hypothesized that the immune system at a steady state (in the absence of inflammatory stimuli) produces TGF-β, which induces the generation of Tregs in the periphery. During an acute-phase response, IL-6 is produced, which inhibits the generation of Tregs but induces the development of Th17 effector cells. The detection of IL-6 as well as of IL-17 and IFN-γ in the supernatant of cultured T cells isolated from capsular tissue supports the hypothesis that the immune system is perpetually activated in the presence of a silicone mammary implant (29) . This sequence of events from initial inflammation to final fibrosis is, of course, also true for fibrotic side effects of other types of siliconebased medical devices, such as gastric bands applied in morbidly obese patients (Figure 3f ).
EMT: epithelial-tomesenchymal transition
Spontaneous Fibrosis Spontaneous keloids. Regarding "spontaneous" fibrosis, e.g., "spontaneous" keloids, we have doubts that these evolve without a primary, albeit unknown, damaging event. However, anecdotal single reports about spontaneous keloid formation can be found in the literature (137, 138 ).
Peyronie's disease and Dupuytren's disease. Penile fibromatosis or Peyronie's disease is a localized fibromatosis in the tunica albuginea of the penis, leading to penile deformation, erectile dysfunction, and/or pain. Palmar fibromatosis, or Dupuytren's disease, is characterized by fibrotic nodule and cord formation with progressive contraction of the palmar fascia resulting in finger flexion deformity. Both diseases seem to be age-dependent and to become manifest between the fourth and seventh decades. The etiology of both conditions is still enigmatic. A combination of environmental factors, especially mechanical stress and smoking, and genetic predisposition seems to promote pathogenesis (139) . Damage to and occlusion of the microvasculature is likely to be a triggering event (140) . Gene expression data and immunological analyses revealed early perivascular accumulation of naive and activated CD3 + T cells (Figure  3g) , antigen-presenting DCs, stress-protein expression (e.g., HSP47, HSP60, HSP70), and proinflammatory cytokines (e.g., macrophage migration inhibitory factor-1, myeloid-related protein-8/14) to be present near occluded vessels in these diseases. Thus, a genetically determined pathological response to localized (traumatic) stress factors might affect the microvasculature, leading to localized ischemia and the generation of oxygen-free radicals, subsequently eliciting an inflammatory reaction in these diseases (141) . This inflammatory event is followed by the production of profibrotic agents, notably TGF-β1, which subsequently promote ECM synthesis and/or remodeling (Figure 3h) . Thus, fibroblast transdifferentiation into myofibroblasts, which are essential cellular components, is present in both fibrotic diseases.
Tumors
In this review, the term "tumor" is used synonymously with the classical term "neoplasm." In principle, tumors can develop from cells originating from any of the three blastodermic layers, i.e., the ectoderm, endoderm, and mesoderm. By definition, mesodermal tumor cells can produce ECM molecules, although this is not the case at first sight for ectoderm-or endoderm-derived tumors. However, these latter cell types can undergo epithelial-to-mesenchymal transition (EMT) under inflammatory conditions. A chronic inflammatory microenvironment has long been recognized as conducive for tumorigenesis, as shown, for instance, by the increased risk for pancreatic cancer in patients with pancreatitis (142) . Thus, inflammation, carcinogenesis, and fibrosis triggered by profibrotic cytokines produced by both inflammatory and tumor cells are intimately intertwined processes.
It is therefore important to realize that a chronic inflammatory microenvironment is a common denominator of all tumors and is responsible for tumor-associated fibrosis (Figure 3i) . Even tumors developing on a clear-cut primary genetic basis, e.g., neurofibromatosis, are accompanied by distinct inflammatory infiltrations, with abundant mast cells representing the first hallmark (143) . Stem cell factor-dependent c-kit signaling is triggered by activation of Ras, followed by modulation of proliferation and cytokine synthesis via the Raf-ERK-p38-Akt pathway. As a matter of fact, as already mentioned above, stem cell factor-stimulated mast cells produce a variety of factors involved in the development of fibrosis, such as tryptase, histamine, heparin, MMPs, IL-6, and TNF-α as well as chemokines (CCL2, CCL3, CCL4, and C5a) and growth factors [e.g., nerve growth factor, vascular endothelial growth factor (VEGF), PDGF, FGF-β, and TGF-β1].
EMT of parenchymal tumor cells, e.g., in renal or pancreatic carcinoma, is crucial for both tumor-associated fibrosis and metastasis (144) . Here, the induction of the Zinc-finger transcription factor Snail, which is induced by TGF-β1, is of special importance (145) . Snail strongly represses E-cadherin in normal and malignant epithelial cells, thus inducing EMT and an invasive tumor phenotype. TGF-β1-triggered Snail expression depends on the MAPK signaling pathway but is independent of Smad4 activity. FGF-β cooperates with TGF-β1 in inducing the Snail promoter, and in addition to the metastasis-facilitating effect, EMT also leads to fibrosis. Snail is also able to indirectly induce the expression of genes encoding mesenchymal proteins, such as vimentin and α-smooth muscle actin, as well as to directly induce pro-type I collagen. Thus, TGF-β1 acts in a paradoxical way in tumor biology: Early in tumorigenesis it is a tumor suppressor, but later it promotes tumor progression, invasion, metastasis, and fibrosis.
Hypoxia can also reactivate developmental embryonic EMT programs that converge in the activation of the NF-κB pathway (the latter is also induced by the inflammatory cytokines TNF-α and IL-1 and by oxidative stress). Thus, in tumors "these EMT programmes, in an unsuccessful attempt to repair the injured tissue, turn to a sinister role and lead to the destruction of epithelial homeostasis and accumulation of extracellular matrix in fibrosis, and to the progression of carcinomas towards the metastatic state" (144, p. 305).
Tumor cells can trigger the activation of NF-κB, the main transducer of inflammation. Inflammatory cytokines then recruit both members of the innate (macrophages) and adaptive (T cells) immune system to the tumor-stromal interface, where tumorassociated macrophages and cancer-associated fibroblasts cooperate in the expression of NF-κB and hypoxia-inducible factor-1α (HIF-1α), promoting tumor progression, metastasis, angiogenesis, and fibrosis. HIF-1α is a potent transcriptional regulator of oxygen-dependent expression of genes such as VEGF and TGF-β1 (146). Importantly, HIF-1α can also directly activate the expression of EMT-inducing transcription factors, notably Snail. In conclusion, inflammation induced by mechanisms of the innate and adaptive immune systems is a hallmark of the presence of tumors and is primarily designed to fight tumor progression, but inflammation also contributes to metastasis and tumor-associated fibrosis.
ANTIFIBROTIC THERAPY
Although substantial progress has been made in understanding the pathogenesis of fibrotic disorders, there is still no cure. Early identification and subsequent elimination or control of the trigger of the particular fibrotic disease is still the best approach for successful treatment. A successful elimination of the causative pathogen, for example, is associated with regression of fibrosis in HBV-and HCV-infected individuals as well as in schistosomiasis patients (147, 148) .
Surgery is still the standard treatment for Dupuytren's contracture, for capsular contracture formed around implants, and for hypertrophic scarring. The fibrotic tissue is excised, but relapses are frequent. Injection of collagenase from Clostridium histolyticum, as a nonsurgical and therefore less invasive option, has been described recently for Dupuytren's disease. Collagenase significantly reduced contractures and improved the range of motion in affected joints. In addition to mild local side effects (e.g., swelling, bruising, pruritus), tendon ruptures have also been described after collagenase treatment owing to uncontrolled digestion of neighboring collagenous structures (149) .
As emphasized throughout this review, a key regulator in the pathogenesis of fibrosis is TGF-β1. It is a pleiotropic cytokine that, in addition to its role in fibrogenesis, has essential functions in immune regulation, angiogenesis, and normal tissue repair. Therefore, it is not surprising that anti-TGF-β1 antibody therapy Wnt: Wingless type in SSc patients increased morbidity and mortality in a placebo-controlled phase I/II trial. Moreover, it showed no efficacy on fibrosis itself (150) . Instead, targeting downstream effectors of TGF-β1, especially those of nonclassic signaling pathways, might be more selective. Imatinib, a small-molecule tyrosine kinase inhibitor that targets both the TGF-β and PDGF signaling pathways, has been shown to inhibit the development of fibrosis and to induce regression of preexisting fibrosis in experimental animal models of fibrosis (151) . Although early reports were promising and the results from a phase II single-arm open-label clinical trial showed modest improvement in cutaneous diffuse SSc, imatinib was poorly tolerated and not effective in a randomized, placebo-controlled, double-blind trial in patients with IPF (152, 153) . In contrast to TGF-β1, TGF-β2 can act as an antifibrotic cytokine. Whereas ZhangHoover & Stein-Streilein (131) demonstrated an indirect antifibrotic effect of this cytokine via the induction of tolerogenic antigenpresenting cell-dependent CD8 + Tregs in a murine model of autoimmune pulmonary interstitial fibrosis, our group has shown a direct antifibrotic effect of TGF-β2 in the UCD-200 chicken model of SSc (80) . Another approach to avoid the adverse effects associated with TGF-β1 inhibition could be to target CTGF or CCN2 instead. CTGF-neutralizing antibodies ameliorated TGF-β-induced fibrosis in mice, and CTGF inhibition with siRNA prevented CCl 4 -induced liver fibrosis in rats (154, 155) . Furthermore, in vivo overexpression of CCN3, a CCN family member that is thought to block the fibrogenic action of CTGF, resulted in reduced type I collagen accumulation and decreased glomerulosclerosis in anti-Thy1.1-induced experimental glomerulonephritis (156) . Another promising therapeutic option is the use of peroxisome proliferator-activated receptor gamma (PPARγ) agonists. PPARγ has been implicated in the regulation of vascular biology, inflammation, and fibrosis and directly modulates TGF-β signaling. PPARγ agonists, such as rosiglitazone, ameliorate schistosome-induced murine hepatitis as well as bleomycin-induced fibrosis (157, 158) . Recent studies have identified additional key molecules and pathways of fibrogenesis that might be potential therapeutic targets. These include the Wnt/β-catenin signaling pathway, the Notch pathway, and hedgehog signaling (159) (160) (161) . However, positive in vitro and in vivo results from animal models do not always translate into effective therapy in humans. Therefore, results from clinical trials are urgently awaited.
CONCLUSION
When we set out to write this review, our thoughts on the immunology of fibrosis reflected the results of our own work focusing on SSc, atherosclerosis, and silicone implantassociated fibrosis. Based on these data, we arrived at two important conclusions: (a) There is no fibrosis without prior inflammation, and (b) irrespective of the underlying primary cause, the final pathways of fibrogenesis are very similar and stereotypical. The evaluation of the vast literature on this topic beyond our own fields of expertise gave further credence to these conclusions, and in this review we provide ample supporting evidence by describing the development of fibrosis under different conditions in various organ systems.
There are, of course, still several open questions that await clarification. For instance, in many papers dealing with profibrotic cytokines, the isotype of TGF-β is not mentioned, and whereas in our hands TGF-β2 was clearly antifibrotic, some other authors describe it as being profibrotic. Furthermore, the role of Th17 cytokines in fibrogenesis is still a matter of debate: Are they only proinflammatory, or are they also profibrotic? Do they even exert protective effects against fibrosis? And we cannot completely exclude the possibility that in rare instances fibrosis may emerge without concomitant inflammation, e.g., by activation of an alternative rather than the canonical Wnt signal transduction pathway. Finally, we have
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